Barclays Raises Danaher (DHR) Price Target to $260
Key Points
- Barclays maintained its Overweight rating on Danaher Corporation on October 22, 2026, while raising its price target from $255.00 to $260.00.
- Barclays's $260 price target implies 13.17% upside from Danaher Corporation's ($DHR) current $229.74 share price.
- Capital International Investors grew its holdings by 1,489,759 shares, ending with 15,504,420 shares worth about $3.57 billion.
- Danaher shares recently traded around $229.98, closing at $230.01 on October 22, 2026.
Get Danaher text alerts
We text you when insiders, Congress, analysts or big funds move on $DHR.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Danaher Corporation alert may contain errors. Disclosures
Barclays maintained its Overweight rating on Danaher Corporation (NYSE: DHR) on October 22, 2026, while raising its price target from $255.00 to $260.00. The research note outlines the firm's forward-looking outlook for the life sciences and diagnostics company. Other firms updated their views on the same day, adding to a busy session of analyst updates for the stock.
DHR
Danaher Corporation
Barclays vs. the S&P 500
Hypothetical returns from Barclays's disclosed trades, not real profit or advice. How we model this.
Barclays's Call on Danaher
Barclays reaffirmed its positive stance on Danaher on October 22, 2026, keeping an Overweight rating while bumping its target price up by $5.00 to $260.00. The adjustment places the firm's target slightly above the broader market average while reflecting confidence in the healthcare firm's operational segments.
Other Institutional Activity in Danaher
Capital International Investors grew its holdings by 1,489,759 shares, ending with 15,504,420 shares worth about $3,566,249,156.
Danaher Corporation Stock Up 2.5%
Danaher shares recently traded around $229.98, sitting below the 52-week high of $242.80 and well above the 52-week low of $160.93. The stock closed at $230.01 on October 22, 2026.
$DHR price target
Danaher Corporation daily closes and this analyst's $260 target. Not advice.
Recent Earnings
Danaher posted trailing twelve month revenue of $25,106,992,960 and earnings of $6.04 per share.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
5 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 5.3%. Revenue missed estimates by 1.8%.
-
Profit surprise
EBITDA missed by 22 percent. Operating income missed by 23 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 5 target cuts.
-
Earnings quality
Gross margin down 1.1 points. Positive free cash flow.
Earnings Call Summary
Danaher started 2026 solidly with adjusted earnings per share of $2.06, up 9.5 percent year over year, beating the consensus of $1.95. Revenue came in at $5.951 billion, slightly below the $6.057 billion expected, due mainly to a lighter respiratory season at Cepheid being down roughly 25 percent. However, strong bioprocessing momentum, with consumables up high single digits and equipment orders surging over 30 percent year over year for the first time in nearly two years, offset weakness. Diagnostics and Life Sciences showed pockets of improvement, with Beckman Coulter diagnostics growing mid single digits outside China and newer products like the Xpert GI panel gaining traction.
Guidance Management raised full year adjusted earnings per share to $8.35 to $8.55 from the prior range. Revenue guidance remains 3 percent to 6 percent growth for the full year, with lower respiratory sales of $1.6 billion to $1.7 billion offset by better core growth elsewhere. Second quarter expected to show low single digit core revenue growth with operating margins around 26.5 percent.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Dividend
Danaher pays an annual dividend rate of $1.60 per share, giving it a dividend yield of 0.71% based on a payout ratio of 25.7%.
Insider Buying and Selling at Danaher Corporation
Director Alan G. Spoon sold 1,358 shares on May 1, 2026, at an average price of $174.67 for a total value of $237,207. Later, Chief Executive Officer Rainer M. Blair sold 58,255 shares on August 21, 2026, for a total value of $12,736,095.
Analysts Set New Price Targets
Barclays maintained an Overweight rating with a target moved from $255.00 to $260.00 on October 22, 2026. JP Morgan maintained an Overweight rating with a target raised from $250.00 to $270.00 on the same day. TD Cowen maintained a Buy rating with a target moved from $255.00 to $270.00, Stifel maintained a Buy rating with a target moved from $220.00 to $260.00, and Baird maintained an Outperform rating with a target raised from $246.00 to $254.00. Across 22 analyst opinions, the stock carries a consensus recommendation of strong buy with a mean price target of $247.18.
About Danaher
Danaher Corporation designs and markets professional, medical, research, and industrial products across biotechnology, life sciences, and diagnostics segments worldwide.
Bottom Line
Barclays stands alongside other major institutions in backing the healthcare provider's path forward. Investors will monitor upcoming earnings reports to see how the company's diagnostics and biotechnology units perform against these rising expectations.
Related Filing Alerts
Source: Barclays's rating change on $DHR (Oct 22, 2026). Written by software, not financial advice. How we make alerts